I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.21
    -0.04 (-0.94%)

    Market Cap: $13.75M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(5/14)
    Avg Surprise
    -392.79%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.73
    Range$-0.96 - $-0.57
    3 analysts
    EPS RevisionsNo revisions (7d)
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-1.50-105.5%
    60d ago$0.00+100.0%
    30d ago$-0.84-15.5%
    7d ago$-0.66+9.6%
    Current$-0.73
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.76
    Range$-1.70 - $0.72
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.76---
    Sep 26EST
    		-$-0.73---
    Jun 26
    Reported Aug 6
    		$-1.11$-0.81-37.04%Miss-753.8%
    Mar 26
    Reported May 7
    		$-0.96$-1.09+11.93%Beat+82.5%
    Dec 25
    Reported Mar 27
    		$-1.21$-0.05-2317.20%Miss-3.3%
    Sep 25
    Reported Nov 6
    		$-1.50$-1.50+0.00%Beat+76.0%
    Jun 25
    Reported Aug 7
    		$-0.13$-0.16+18.75%Beat+98.6%
    Mar 25
    Reported May 13
    		$-5.50$-3.25-69.23%Miss+35.3%
    Dec 24
    Reported Mar 13
    		$-1.17$-0.22-431.82%Miss-405.6%
    Sep 24
    Reported Nov 13
    		$-6.25$-7.62+17.98%Beat-47.1%
    Jun 24
    Reported Aug 8
    		$-9.00$-8.00-12.50%Miss+65.7%
    Mar 24
    Reported May 9
    		$-8.50$-0.34-2400.00%Miss-2079.5%
    Dec 23
    Reported Mar 14
    		$-0.23$-0.18-28.56%Miss+3.6%
    Sep 23
    Reported Nov 13
    		$-4.25$-2.25-88.89%Miss-767.3%
    Jun 23
    Reported Aug 14
    		$-26.25$-10.00-162.50%Miss-
    Mar 23
    Reported Jun 30
    		$-0.39$-0.39+0.00%Beat-
    Sep 21
    Reported Oct 28
    		$-0.24$0.00N/AMiss-
    Jun 21
    Reported Sep 20
    		$-0.49$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.88EV/EBITDA-4.72x
    Price/FCF-1.27xFCF Yield-78.58%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-195.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.00xQuick Ratio5.00x
    Trading Statistics
    Beta3.03Avg Volume37.79K
    52-Week High$43.5052-Week Low$3.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.51
    SMA 20$4.33
    SMA 50$4.40
    SMA 200$6.75
    EMA 10$4.40
    EMA 20$4.39
    EMA 50$4.44
    EMA 200$7.50

    MACD

    Line: 0.02Signal: 0.02Hist: -0.01

    ADX

    ADX: 18.8+DI: 18.9-DI: 16.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down56.0
    PSAR$4.14

    Bollinger Bands

    Upper Band$4.91
    Lower Band$3.75
    %B Position2660%(Upper)
    Band Width0.40

    RSI (14-Day)

    Neutral
    45.0

    Momentum Oscillators

    Stoch %K27.0
    Stoch %D38.2
    Williams %R-75.6
    ROC (10d)1.4%
    Momentum0.06
    CCI (20d)-38.1
    MFI (14d)41.5

    Volatility Measures

    ATR (14d)$0.33(7.7%)
    StdDev (20d)0.29
    Hist Vol75.7%(High)

    Volume Flow

    VWAP$4.23
    OBV1.1B
    AD Line398.1B
    CMF (20d)-0.202

    Volume Metrics

    Avg Vol (20d)39.1K
    Vol Ratio0.2x(Low)
    VWMA (20d)$4.42

    Pivot Points

    R3$4.84
    R2$4.71
    R1$4.48
    Pivot Point$4.35
    S1$4.12
    S2$3.99
    S3$3.76

    Advanced Oscillators

    TSI1.83
    Ultimate Osc39.3
    KST9.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-26,000$0$0$0$24,000$0$0$0$282,216$0
    Cost of Revenue$0$0$7,000$0$0$0$12,000$0$0$0$5,892$0
    Gross Profit$0$0$-7,000$0$0$0$12,000$0$0$0$276,324$0
    Operating Expenses$3.08M$2.53M$3.14M$2.73M$2.71M$3.39M$3.20M$3.57M$5.07M$4.74M$3.35M$2.49M
    R&D$1.83M$1.20M$1.50M$1.55M$1.54M$2.19M$1.97M$2.15M$3.56M$2.81M$1.80M$1.35M
    SG&A$1.25M$1.33M$1.64M$1.18M$1.16M$1.21M$1.24M$1.42M$1.51M$1.93M$1.55M$1.14M
    Operating Income$-3,084,000$-2,526,000$-3,140,000$-2,733,000$-2,705,000$-3,394,000$-3,203,000$-3,570,000$-5,069,000$-4,743,000$-3,353,000$-2,491,000
    Interest Income$77,000$94,000$89,000$59,000$17,000$15,000$28,000$48,000$98,000$140,000$176,000$148,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,007,000$-2,434,000$-3,051,000$-2,671,000$-2,537,000$-3,347,000$-3,181,000$-3,513,000$-4,971,000$-4,603,000$-3,196,000$-2,329,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,007,000$-2,434,000$-3,051,000$-2,671,000$-2,537,000$-3,347,000$-3,181,000$-3,513,000$-4,971,000$-4,603,000$-3,172,000$-2,329,000
    EBITDA$-3,077,000$-2,521,000$-3,140,000$-2,730,000$-2,547,000$-3,356,000$-3,209,000$-3,561,000$-5,069,000$-4,737,000$-3,353,000$-2,477,000
    EBIT$-3,084,000$-2,528,000$-3,140,000$-2,730,000$-2,554,000$-3,362,000$-3,209,000$-3,561,000$-5,069,000$-4,743,000$-3,353,000$-2,477,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INTS

    News

    H.C. Wainwright reiterates Buy on Intensity Therapeutics stock

    H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Intensity Therapeutics (NASDAQ:INTS) stock, despite the company reporting a larger-than-expected loss for Q2 2026. The stock is currently trading near its Fair Value of $4.30, and the company is resuming enrollment for its INVINCIBLE-3 Study in the U.S. and plans to do so in the EU, contingent on additional funding.

    Investing.com•8/20/26•
    Bullish

    H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $7

    H.C. Wainwright has reiterated its Buy rating for Intensity Therapeutics (INTS.US) and maintained its price target of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomoo•8/19/26•
    Bullish

    H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $7

    H.C. Wainwright has reiterated its Buy rating for Intensity Therapeutics (INTS.US) but has lowered the price target from $11 to $7. This adjustment follows the company's second-quarter earnings report.

    Moomoo•8/19/26•
    Somewhat-Bearish

    H.C. Wainwright reiterates Buy on Intensity Therapeutics stock

    H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Intensity Therapeutics (NASDAQ:INTS), despite the stock trading below the analyst consensus range. The company recently reported a larger-than-expected loss for Q2 2026 and is resuming enrollment for its INVINCIBLE-3 Study in the U.S. and plans to do so in Europe, contingent on additional funding. Intensity Therapeutics holds more cash than debt and has a strong current ratio, indicating solid near-term liquidity.

    Investing.com•8/19/26•
    Somewhat-Bullish

    INTENSITY THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $7 FROM $5

    H.C. Wainwright has increased its target price for Intensity Therapeutics, Inc. (INTS.O) shares to $7, up from the previous $5. This adjustment reflects an updated outlook on the company's financial prospects by the analyst firm. The article, sourced from Reuters, highlights this specific change in analyst rating.

    Bitget•8/18/26•
    Neutral

    Frequently Asked Questions About INTS

    Does INTS pay dividends?
    Intensity Therapeutics, Inc. Common stock (INTS) does not currently pay a regular dividend.
    What is INTS's market cap?
    Intensity Therapeutics, Inc. Common stock (INTS) has a market capitalization of $13.75M with a current stock price of $4.21.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In